Skip to main content
      EULAR 2025 - Day 1 Report

      Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered,

      Dr. John Cush RheumNow

      3 months ago
      EULAR 2025 - Day 1 Report Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1. https://t.co/ycQT2dfVXe https://t.co/Qa58ofW411
      Health Literacy Matters in Rheumatic Disease Care

      Dr. Mrinalini Dey reports on abstract OP0026, "Health literacy associ

      Dr. John Cush RheumNow

      3 months ago
      Health Literacy Matters in Rheumatic Disease Care Dr. Mrinalini Dey reports on abstract OP0026, "Health literacy associates with clinical, treatment and work status in people with inflammatory arthritis: Results from a national cohort", presented at EULAR 2025 in Barcelona, https://t.co/f45rxHBYnY
      Highlights from today included presentations on imaging in vasculitis, a debate on whether to treat high risk pre-clinical RA, and EULAR Recommendations on a) Treatment of interstitial lung disease (ILD); b) Physical Activity in people with arthritis; and c) EULAR disease activity score for antiphospholipid syndrome and d) the management of SLE nephritis. Below are a few others that caught my eye today.
      NMA of 14RCTs (>2500 pts) eval relative efficacy of bDMARDs and tsDMARDs in mostly biologic naïve nr-axSpA pts.
      -All

      Adela Castro AdelaCastro222

      3 months ago
      NMA of 14RCTs (>2500 pts) eval relative efficacy of bDMARDs and tsDMARDs in mostly biologic naïve nr-axSpA pts. -All therapies studied significantly improved ASAS40 response rates compared to placebo. -Certolizumab and Golimumab were the most effective therapies, followed by https://t.co/BJLRpEDYrv
      👁️Uveitis in axSpA:
      -Up to 40% can present before SpA dx
      -NMA of 44 RCTs showed tx with TNFi, JAKi and IL-17i prote

      Adela Castro AdelaCastro222

      3 months ago
      👁️Uveitis in axSpA: -Up to 40% can present before SpA dx -NMA of 44 RCTs showed tx with TNFi, JAKi and IL-17i protective effects against uveitis -Low rates of uveitis in axSpA pts on BIME trials suggests its possible beneficial effects. #EULAR2025 @RheumNow https://t.co/mPuSMnD1Zs
      In 30 axSpA pts (mean age 42 yrs, BASDAI 3.5, BASFI 2.8, BASMI 2.0, chest expansion 4.5 cm), an 8-wk individualized exer

      Antoni Chan MD (Prof) synovialjoints

      3 months ago
      In 30 axSpA pts (mean age 42 yrs, BASDAI 3.5, BASFI 2.8, BASMI 2.0, chest expansion 4.5 cm), an 8-wk individualized exercise (cardiorespiratory + trunk strength via cardiopulmonary exercise testing [CPET] & David Back Concept [DBC] devices) ↓ trunk strength deficit 14.1% & https://t.co/505cCEOzu1
      In 631 axSpA pts (mean age 33y, 54% female) from DESIR cohort, high-dose NSAID use (ASAS NSAID index ≥50) not associat

      Antoni Chan MD (Prof) synovialjoints

      3 months ago
      In 631 axSpA pts (mean age 33y, 54% female) from DESIR cohort, high-dose NSAID use (ASAS NSAID index ≥50) not associated with incident hypertension (HR 1.01; 95% CI 0.98–1.02) over 72 months. NSAID anti-inflammatory effect may offset BP risk in axSpA. Abstract#POS0256 @RheumNow https://t.co/ELYWoJDyKJ
      In 4,121 SpA pts (mean age 45y; 61% male), composite scores w/ joint counts (DAPSA, DAS28, DAS44) best discriminated per

      Antoni Chan MD (Prof) synovialjoints

      3 months ago
      In 4,121 SpA pts (mean age 45y; 61% male), composite scores w/ joint counts (DAPSA, DAS28, DAS44) best discriminated peripheral arthritis activity vs PGA & SJC alone. All scores had excellent construct validity; CRP weakest. Composite indices may optimize SpA assessment. https://t.co/oM97BEkkH5
      In phase II/III trial (NCT04481139), ivarmacitinib 4mg significantly improved PROs in active ankylosing spondylitis: tot

      Antoni Chan MD (Prof) synovialjoints

      3 months ago
      In phase II/III trial (NCT04481139), ivarmacitinib 4mg significantly improved PROs in active ankylosing spondylitis: total back pain VAS (-25.6 vs -17.0), night pain (-25.0 vs -14.3), stiffness (-24.5 vs -15.8), PtGA (-23.8 vs -13.3), ASQoL (-3.2 vs -2.4). Benefits seen even https://t.co/RcJ5vfdoHf
      In clinical practice, not all US enthesitis findings are SpA-specific. Enthesophytes/calcifications common in healthy pt

      Antoni Chan MD (Prof) synovialjoints

      3 months ago
      In clinical practice, not all US enthesitis findings are SpA-specific. Enthesophytes/calcifications common in healthy pts. Inflammatory lesions (PD signal, erosions) at Achilles, distal patella & greater trochanter better distinguish PsA/axSpA. Target key sites to improve US https://t.co/jO61QjKfQp
      In 581 PsA pts (EuroSpA), MRI showed axial SpA features in 31%: BME (69%), erosions (68%), fat lesions (58%). MRI-axPsA

      Antoni Chan MD (Prof) synovialjoints

      3 months ago
      In 581 PsA pts (EuroSpA), MRI showed axial SpA features in 31%: BME (69%), erosions (68%), fat lesions (58%). MRI-axPsA pts: younger (41y vs 46y), male (70%), HLA-B27+ (55%), ↑CRP (13 vs 7 mg/L). Radiographs identified sacroiliitis in 29%. MRI adds key detection. POS0297 https://t.co/nAw0BDAH22
      Using high-resolution peripheral quantitative computed tomography (HR-pQCT), patients with psoriatic arthritis (PsA) &am

      Antoni Chan MD (Prof) synovialjoints

      3 months ago
      Using high-resolution peripheral quantitative computed tomography (HR-pQCT), patients with psoriatic arthritis (PsA) & psoriasis (PsO) show reduced cortical volumetric bone mineral density (vBMD) & thinner cortex vs controls. Bone mechanics impaired: reduced stiffness & failure https://t.co/ghH2cwOYJc
      #Shingrix #vaccination is Impt in #SLE
      HZ vaccination works in SLE, safe – 1yr still good humeral & cellular immun

      Janet Pope Janetbirdope

      3 months ago
      #Shingrix #vaccination is Impt in #SLE HZ vaccination works in SLE, safe – 1yr still good humeral & cellular immunity -attenuation over 1 yr re #immune #responses No major flares #shingles is ⬆️ in #lupus 👇 abnormal immune response #pred, #MMF #IS POS1005 #EULAR2025 @RheumNow https://t.co/o8lDXgOhE1
      How does #HCQ work in #SLE

      Stabilizes lysomal membranes?

      #Lupus pts on HCQ monoRx & low #SLEDAI were followed

      Si

      Janet Pope Janetbirdope

      3 months ago
      How does #HCQ work in #SLE Stabilizes lysomal membranes? #Lupus pts on HCQ monoRx & low #SLEDAI were followed Single cell seq HCQ cytokine sigs May vary over time IFN & OXPosph pathways #Hydroxychloroquine in #LN - #IFN I&II #EULAR2025 @RheumNow POS0983 https://t.co/0gMQh9MNlg
      #TDM for #HCQ warns of #toxic #levels in #CRF

      v low GFR <30, <60, <90, >90
       
      400mg/d all in low GFR toxic

      Janet Pope Janetbirdope

      3 months ago
      #TDM for #HCQ warns of #toxic #levels in #CRF v low GFR <30, <60, <90, >90   400mg/d all in low GFR toxic   200mg/d 25% in low GFR toxic   6mg/kg/d – low GFR is too ⬆️ adjust HCQ dose for pts with CRF POS0987 #EULAR2025 @RheumNow @eular_org https://t.co/vg2b87LuiE
      ×